Research: Epidemiology

Characteristics of people with high visit-to-visit glycaemic variability in Type 2 diabetes

J. D. Noyes\textsuperscript{1}, E. Soto-Pedre\textsuperscript{2}, L. A. Donnelly\textsuperscript{2} and E. R. Pearson\textsuperscript{2}

\textsuperscript{1}School of Medicine and \textsuperscript{2}Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

Accepted 25 July 2017

Abstract

Aims Increased visit-to-visit glycaemic variability is independently associated with adverse outcomes in Type 2 diabetes. Our aim was to identify the patient characteristics associated with raised visit-to-visit glycaemic variability in people with Type 2 diabetes.

Methods A case–control study was conducted to establish associations between HbA\textsubscript{1c} variability and clinical covariates in 10 130 people with Type 2 diabetes. Variability was calculated by two metrics [SD and coefficient of variation (CV)] from a minimum of four HbA\textsubscript{1c} readings obtained over a 4-year period. High and low variability groups were defined as the top and bottom tertile of the SD or CV, and used in logistic regression analyses including a number of clinical and biochemical covariates. The analyses were stratified into low mean (< 53 mmol/mol; 7\%) and high mean (≥ 53 mmol/mol; 7\%) HbA\textsubscript{1c} groups.

Results Findings were consistent across both HbA\textsubscript{1c} groups and variability metrics. Treatment, independent of other factors, was the most strongly associated covariate for the risk of high HbA\textsubscript{1c} variability. A six-fold increased risk was observed in the low HbA\textsubscript{1c} group, between the most and least intense treatment regimens ($P < 0.001$). Similar findings were present in the high HbA\textsubscript{1c} group with a three-fold increase in risk ($P < 0.001$). In addition, male gender, younger age, reduced HDL-cholesterol and increased BMI were all found to be independently associated with raised visit-to-visit glycaemic variability.

Conclusions Intensive treatment resulting in low mean HbA\textsubscript{1c} was associated with marked increase in HbA\textsubscript{1c} variability. Irrespective of diabetes control, the greatest visit-to-visit variability was observed in young, insulin resistant men.

Diabet. Med. 35, 262–269 (2018)

Introduction

Pivotal studies over the years have demonstrated the beneficial effects of lowering HbA\textsubscript{1c} on both micro- and macrovascular complications in Type 2 diabetes [1,2]. However, on-going debate exists as to whether other factors, such as glycaemic variability, play a contributory role in the adverse outcomes of diabetes.

Glycaemic variability is the measure of glycaemic fluctuations over a given time. Clinically, it is an umbrella term for two distinct measurements: intraday variability (short-term) and visit-to-visit variability (long-term). HbA\textsubscript{1c} is most often used as the measure of glycaemia in the latter. Currently, no ‘gold standard’ metric exists to measure HbA\textsubscript{1c} variability, however, it is most commonly expressed as either the standard deviation (SD) or coefficient of variation (CV) of the glycaemia measures.

Many studies in Type 2 diabetes cohorts have shown positive associations between raised visit-to-visit variability and adverse outcomes, independent of mean HbA\textsubscript{1c} level. A recent meta-analysis identified that renal disease, cardiovascular disease and mortality were all independently associated with raised HbA\textsubscript{1c} variability [3]. This analysis included 13 studies, the largest of which contained > 4000 participants [4]. Research in the field of intraday variability has shown that certain patient features and clinical factors are associated with raised short-term glycaemic variability [5–8]. However, we identified no similar studies in the field of long-term glycaemic variability.
What’s new?

- Increased visit-to-visit HbA1c variability has previously been associated with increased risk of adverse outcomes, including microvascular and macrovascular disease.

- We determined the patient characteristics associated with raised visit-to-visit glycaemic variability, independent of the mean HbA1c level and established that these people with highly variable Type 2 diabetes have increased cardiovascular disease risk factors including male gender, raised BMI and reduced HDL-cholesterol compared with those with low variability.

- People with Type 2 diabetes receiving greater intensity of treatment (e.g. insulin treatment or triple oral therapy) have greater visit-to-visit variability than those who are diet or monotherapy treated.

The detrimental consequences of high intraday variability have been mapped at a cellular level and are well documented [9–12]. The cellular effects of elevated HbA1c variability are unknown, which gives rise to the possibility that two distinct biological processes are occurring. Establishing whether the same patient characteristics are associated with both raised intraday and HbA1c variability is of interest because the findings could provide an insight into the biological processes responsible for increased HbA1c variability and its associated adverse outcomes.

The aim of our research was to identify the patient characteristics associated with the risk of raised HbA1c variability in a large Type 2 diabetes cohort.

Participants and methods

Study setting and design

A case–control study of HbA1c variability was conducted in Tayside and Fife (Scotland, UK). Data were gathered from the Scottish Care Information-Diabetes Collaboration (SCI-DCC); the electronic health record system used in Scotland for people with diabetes. We identified a source population of 13,285 individuals with Type 2 diabetes. Biochemical, demographic and prescribing data were available for these participants across a 20-year period since 1994.

Participants with at least four HbA1c recordings within a 4-year window of time between 1 January 2010 and 1 January 2014 were included in this study (Fig. 1). Baseline data on covariates were gathered at 1 January 2010 (± 6 months). If a participant had more than one covariate recording, the mean of these values was calculated. For those with more than one treatment therapy recorded, the latest listed was used for the analysis; this treatment was the most likely to be continued due to the stepwise progression of diabetes management.

Each participant had their glycaemic variability defined by two metrics; the SD and the CV, which was 100 × SD/mean HbA1c. Two HbA1c variability groups were then constructed encompassing the top tertile of the distribution (high variability = cases) and bottom tertile of the distribution (low variability = controls) respectively (Fig. 2). This process was carried out for both SD and CV.

Statistical analyses

Analysis of variance (ANOVA) and chi-square tests were used to compare means and frequencies among subgroups of participants respectively. Tests of association with HbA1c variability (coded as binary, high = case vs. low = control) were performed using unconditional logistic regression models. Univariate models were used to determine the patient characteristics associated with glycaemic variability, and potential determinants (gender, age, duration of Type 2 diabetes, diabetes treatment, HDL-cholesterol, BMI, social deprivation and number of HbA1c readings) were considered in the analysis. We then developed a multivariate model, including covariates where the univariate P-value for the trait association was ≤ 0.2 [13]. This analysis was carried out for both variability metrics (i.e., SD and CV). We used the goodness-of-fit approach described by Hosmer and Lemeshow to test how well the derived model fitted the data [14]. Two-way interactions were additionally tested for between participant gender and the other covariates included in our final multivariate model.

Preliminary analyses revealed a strong positive association between mean HbA1c level and high variability. Subsequently, the data were stratified into two groups based upon mean HbA1c level. The HbA1c value of 53 mmol/mol (7.0%) was selected as the cut-off, creating a low mean HbA1c group (< 53 mmol/mol; 7.0%) and a high mean HbA1c group (≥ 53 mmol/mol; 7.0%) which were used in all subsequent analyses. This HbA1c cut-off of 53 mmol/mol (7.0%) was chosen for two reasons: first, it split our sample distribution into two groups with a large number of participants in each; and second, it is a clinical target for HbA1c treatment in people with Type 2 diabetes [15].

![FIGURE 1 Depiction of the retrospective data collection process.](image-url)
Sensitivity analyses were performed to determine if extreme mean HbA1c values were driving the analyses and whether insulin treatment, in isolation, was associated with increased variability. The first analysis removed all participants with a mean HbA1c $<48$ mmol/mol (6.5%) and $>75$ mmol/mol (9.0%) from the cohort, after which the previously described multivariate analysis was carried out. The second sensitivity analysis was a whole sample multivariate analysis in which the three previously used treatment groups were broken down into five individual categories to specifically focus on any potential associations between the use of insulin and variability. The final sensitivity analysis carried out addressed the issue of therapy changes across the 4-year HbA1c collection window. Participants who had a different final treatment from their baseline recording were removed prior to the creation of the model. Statistical analyses were conducted using STATA/SE version 14 software (StataCorp, College Station, TX, USA), and the statistical significance level set at $P < 0.05$.

**Results**

Some 10,130 participants were included in the analysis and their baseline characteristics are shown in Table 1. A total of...
3378 participants were categorised as having low HbA1c variability, of whom 2709 had a mean HbA1c $< 53$ mmol/mol (7.0%) and 669 had a mean HbA1c $\geq 53$ mmol/mol (7.0%). The high HbA1c variability group contained 3376 participants, of whom 348 had a mean HbA1c $< 53$ mmol/mol (7.0%) and 3028 had a mean HbA1c $\geq 53$ mmol/mol (7.0%). The characteristics of the 1030 people with Type 2 diabetes excluded from the analysis due to an insufficient number of HbA1c readings are shown in Table S1.

Similar results were observed using both the SD and CV as a measure of HbA1c variability. However, the ‘goodness of fit’ score in the logistic regression models was superior when using the SD compared to the CV. Therefore, the results of the analysis are presented purely for the SD.

Univariate logistic regression revealed that a number of covariates were associated with HbA1c variability in both the low and high mean HbA1c strata (Table S2). The low mean HbA1c analysis found that: men had greater odds of having high HbA1c variability compared with women [ odds ratio (OR) 1.45, 95% CI 1.16–1.82, $P = 0.001$]; participants aged $< 55$ years were more likely to be highly variable compared with those aged 75 years and older (OR 3.05, 95% CI 2.12–4.39, $P < 0.001$); and both lower HDL-cholesterol and higher BMI were associated with raised HbA1c variability. Participants treated with medication had markedly increased variability compared with those whose diabetes was diet controlled. The odds of high HbA1c variability were greater in the ‘triple or insulin’ group compared with the ‘mono or dual’ therapy group. Finally, a short duration of diabetes was marginally associated with lower risk of high HbA1c variability. Similar results were seen in the high mean HbA1c group, although the previously observed protective effect regarding duration of Type 2 diabetes was not significant in this analysis.

The results of the stratified multivariate logistic regression models are shown in Table 2. The models were adjusted for social deprivation and the number of HbA1c measures. These multivariate models are consistent with the univariate analysis showing that the previous findings are independent of other variables. The goodness-of-fit scores for the low (chi$^2 = 1736.72, P = 0.82$) and high (chi$^2 = 2219.15, P = 0.72$) mean HbA1c strata models indicated that both fitted the data well. In addition, none of the two-way interactions tested between gender and other covariates were statistically significant. Table 2 shows that those in the ‘triple or insulin’ treatment group were over six times more likely to be highly variable than those whose diabetes was diet treated in the low mean HbA1c strata (OR = 6.64, 95% CI 3.72–11.86, $P < 0.001$). This large increase in risk was also observed in the high mean HbA1c group with a greater than three-fold increase compared with those whose diabetes was diet treated (OR 3.15, 95% CI 2.21–4.47, $P < 0.001$). In addition to this, younger people with Type 2 diabetes when compared with their older counterparts remained far more likely to be highly variable. In both HbA1c strata those $< 55$ years old were more than twice as likely to have high HbA1c variability compared to those aged 75 and older.

Some 6763 participants were included in the first sensitivity analysis, which removed those with low mean HbA1c ($< 48$ mmol/mol; 6.5%) and high mean HbA1c ($> 75$ mmol/mol; 9%). The low variability group contained 2255 participants, of whom 1110 had a mean HbA1c $< 53$ mmol/mol (7.0%) and 1145 had a mean HbA1c $\geq 53$ mmol/mol (7.0%).

### Table 1 Baseline characteristics

| Characteristic | All ($n = 10\, 130$) | Low variability controls ($n = 3378$) | High variability cases ($n = 3376$) | P value (low vs high) |
|---------------|----------------------|---------------------------------------|-----------------------------------|----------------------|
| Gender, $n$ (%) |                      |                                       |                                   |                      |
| Female        | 4628 (45.7)          | 1735 (51.4)                           | 1452 (43.0)                       | $<0.001$             |
| Male          | 5502 (54.3)          | 1643 (48.6)                           | 1924 (57.0)                       |                      |
| Age (years)   | 66.9 (11.1)          | 70.1 (10.4)                           | 64.3 (11.4)                       | $<0.001$             |
| Type 2 diabetes duration (years) | 5.1 (4.0) | 4.5 (3.8) | 5.6 (4.1) | $<0.001$ |
| Treatment, $n$ (%) |              |                                       |                                   |                      |
| Diet          | 3386 (33.4)          | 1805 (53.4)                           | 638 (18.9)                        |                      |
| Mono or dual  | 3456 (34.9)          | 1456 (43.1)                           | 2008 (59.5)                       |                      |
| Triple or insulin | 1288 (12.7) | 117 (3.5%) | 730 (21.6) |                      |
| HbA1c (mmol/L) | 1.22 (0.34)          | 1.32 (0.37)                           | 1.15 (0.31)                       | $<0.001$             |
| BMI (kg/m$^2$)| 31.7 (6.2)           | 30.4 (5.9)                            | 33.0 (6.5)                        | $<0.001$             |
| Social deprivation (SIMD), $n$ (%) |                 |                                       |                                   |                      |
| 1 (most deprived) | 2110 (20.8) | 667 (19.8) | 764 (22.6) |                      |
| 2              | 2189 (21.6)          | 703 (20.8%)                           | 788 (23.3%)                       |                      |
| 3              | 2006 (19.8)          | 627 (18.6%)                           | 682 (20.2%)                       |                      |
| 4              | 1923 (19.0)          | 679 (20.1%)                           | 603 (17.9%)                       |                      |
| 5 (least deprived) | 1902 (18.8) | 702 (20.8%) | 539 (16.0%) |                      |
| No. of readings | 7.9 (2.6)           | 7.0 (2.0)                             | 8.7 (2.9)                         | $<0.001$             |
| HbA1c (mmol/mol) | 57 (12)              | 48 (7)                                | 66 (12)                           | $<0.001$             |
| HbA1c (%)      | 7.4 (1.1)            | 6.5 (0.7)                             | 8.2 (1.1)                         | $<0.001$             |

Values are reported as the mean (SD), unless indicated otherwise.
Table 2 Multivariate whole sample analysis showing the odds of being highly variable

| Variable                              | Low mean HbA1c (n = 3057) | Odds ratio (95% CI) | P-value | High mean HbA1c (n = 3697) | Odds ratio (95% CI) | P-value |
|---------------------------------------|---------------------------|---------------------|---------|---------------------------|---------------------|---------|
| Gender                                |                           |                     |         |                           |                     |         |
| Female                                | 1.00                      |                     |         | 1.00                      |                     |         |
| Male                                  | 1.35 (1.05–1.74)          | 0.018               |         | 1.24 (1.03–1.49)          | 0.023               |         |
| Age, years                            |                           |                     |         |                           |                     |         |
| ≥ 75                                  | 1.00                      |                     |         | 1.00                      |                     |         |
| ≥ 65 to < 75                          | 1.16 (0.86–1.58)          | 0.328               |         | 0.88 (0.70–1.11)          | 0.287               |         |
| 55 to < 65                            | 1.22 (0.87–1.72)          | 0.249               |         | 1.49 (1.16–1.92)          | 0.002               |         |
| < 55                                  | 2.29 (1.51–3.49)          | < 0.001             |         | 2.36 (1.72–3.24)          | < 0.001             |         |
| Type 2 diabetes duration, years       |                           |                     |         |                           |                     |         |
| > 7                                   | 1.00                      |                     |         | 1.00                      |                     |         |
| 2.5–7                                 | 0.86 (0.63–1.16)          | 0.322               |         | 0.95 (0.76–1.18)          | 0.618               |         |
| < 2.5                                 | 0.98 (0.70–1.37)          | 0.904               |         | 1.36 (1.04–1.79)          | 0.026               |         |
| Treatment                             |                           |                     |         |                           |                     |         |
| Diet                                  |                           |                     |         |                           |                     |         |
| Mono or dual                          | 3.02 (2.30–3.96)          | < 0.001             |         | 1.44 (1.14–1.82)          | 0.002               |         |
| Triple or insulin                     | 6.64 (3.72–11.86)         | < 0.001             |         | 3.15 (2.21–4.47)          | < 0.001             |         |
| HDL-cholesterol, mmol/L               |                           |                     |         |                           |                     |         |
| > 1.3                                 | 1.00                      |                     |         | 1.00                      |                     |         |
| 1.0–1.3                               | 1.47 (1.11–1.95)          | 0.007               |         | 1.39 (1.13–1.71)          | 0.002               |         |
| < 1.0                                 | 1.79 (1.29–2.48)          | < 0.001             |         | 1.87 (1.46–2.39)          | < 0.001             |         |
| BMI, kg/m²                             |                           |                     |         |                           |                     |         |
| < 25                                  | 1.00                      |                     |         | 1.00                      |                     |         |
| 25–35                                 | 1.15 (0.78–1.69)          | 0.479               |         | 1.22 (0.90–1.65)          | 0.205               |         |
| > 35                                  | 1.62 (1.05–2.52)          | 0.030               |         | 1.72 (1.22–2.43)          | 0.002               |         |

Adjusted for social deprivation and number of readings.

The high variability group in this analysis contained 2254 participants, of whom 225 had a mean HbA1c < 53 mmol/mol (7.0%) and 2029 had a mean HbA1c ≥ 53 mmol/mol (7.0%). This cohort was used in an identical multivariate model and showed that the same factors were associated with increased HbA1c variability independent of other variables when extreme HbA1c values are removed (Table S3). The goodness-of-fit scores for the low and high mean HbA1c strata were (chi² = 1014.87, P = 0.50) and (chi² = 2058.30, P = 0.40) respectively.

Creating five individual treatment categories in the second sensitivity analysis revealed that those treated with insulin were more likely to be highly variable than those who were taking triple oral therapy in the low mean HbA1c strata; however, this was not seen in the high mean HbA1c group (Table S4). It is important to note that a larger number of participants were taking triple oral therapy or insulin in the high mean HbA1c strata (n = 774) compared with the low mean HbA1c strata (n = 73).

Of the 9804 participants with a documented final drug therapy, 6165 did not change their treatment therapy from baseline and were included in the third sensitivity analysis. The findings from this analysis were in keeping with the results of the previous multivariate analyses (Table S5). Further analysis revealed that 11.2% of participants in the low variability group changed their treatment during the 4 years compared with 58.8% of those in the high variability group.

Discussion

The findings of our analysis revealed that young, insulin-resistant men are most at risk of having high HbA1c variability. In addition, the participant’s prescribed treatment was found to be the largest independent predictor of risk. These findings were seen in both the low mean and high mean HbA1c groups. The choice of variability metric, whether SD or CV, had little effect on the results of our analysis.

Comparing our results with the most similar study identified in the field of short-term variability is of interest. Murata et al. [8] found in a cohort of 204 veterans with insulin-treated Type 2 diabetes that high glucose variability over 8 weeks was associated with older age and a longer diabetes duration. In addition, obesity and those treated with larger insulin doses were found to have lower variability. By contrast, we show the opposite findings for HbA1c variability.
HbA1c variability is likely to be caused by a number of factors, predominantly related to variability in lifestyle, such as exercise [16], high stress [17] and poor treatment adherence [18]. In addition to lifestyle factors, it is also likely that underlying biological mechanisms play a role in HbA1c variability. For example, some people with Type 2 diabetes may be better than others at compensating for increased metabolic demands seen with episodic poor diet or illness. An extreme example of this can be found with glucokinase-maturity-onset diabetes of the young. These people with diabetes have impaired glucose-sensing abilities which result in mildly elevated blood glucose levels [19]. The HbA1c readings of these individuals remain constant regardless of lifestyle and treatment interventions [20], consistent with these individuals being able to compensate for increased demand by increasing insulin secretion. The biological mechanisms underlying HbA1c variability in Type 2 diabetes are not known, and further work is required in this area.

One potential limitation of our study was the positive correlation between mean HbA1c level and HbA1c variability. We wanted to draw associations based solely on HbA1c variability, not mean HbA1c level, which has previously proven associations with both micro- and macrovascular complications. To minimize this effect, we stratified the analysis by mean HbA1c level. The results generated were consistent across both mean HbA1c groups, strongly suggesting that the patient characteristics identified were associated with raised HbA1c variability and not mean HbA1c level. We also undertook a sensitivity analysis removing those with mean HbA1c > 75 mmol/mol (9%) and < 48 mmol/mol (6.5%), and showed similar results to our full model. Another potential limitation to our model was underlying diabetes progression as those progressing rapidly will have a higher so. To minimize the impact of progression we chose a 4-year window for HbA1c readings to accurately assess long-term variability, while limiting the risk of falsely identifying fast progressors as having high HbA1c variability. Finally, we acknowledge that this is an observational study, and although we have adjusted for potential measured confounders (such as social deprivation and number of HbA1c measures) our results could still be affected by unmeasured confounders.

To determine HbA1c variability, multiple HbA1c readings are required. In this study, 1030 participants were excluded due to an insufficient number of HbA1c measures, leaving a select group of people with Type 2 diabetes who have four or more HbA1c readings over 4 years for further analysis. There are several potential clinical reasons why a person with Type 2 diabetes may need to be monitored more closely than another which must be considered when interpreting our results. In this study, the number of readings was adjusted for in all our multivariate models and the baseline characteristics of this excluded cohort were similar to those of the participants included in our final analysis (Table S1).

Some 3639 participants changed their treatment over the 4-year window used to define HbA1c variability, with treatment change being more common in the high variability group than the low variability group. This difference might reflect that those who are more variable are consequently more likely to receive additional treatment (as for a given mean HbA1c, their HbA1c readings are more likely to go high than those with low variability and this may precipitate new treatment). An alternative explanation is that starting a new drug results in a large change in HbA1c that makes the HbA1c recorded during these 4 years more variable (i.e. the HbA1c variability is not a measure of intrinsic variability but is secondary to treatment change). To ensure that this latter scenario was not driving our results, a sensitivity analysis was carried out which showed almost identical results to our main analysis.

The treatment prescribed to a person with Type 2 diabetes was found to be strongly associated with their risk of having highly variable HbA1c. This is particularly striking in the stratum with mean HbA1c < 53 mmol/mol (7%). In this group, the participants who were intensively treated, with triple oral therapy or insulin, to achieve this target had a more than six-fold increased risk of having highly variable HbA1c. Within this group, greater variability again was seen in those on insulin compared with triple oral therapy, although the numbers were small. A similar pattern is seen in the stratum with HbA1c ≥ 53 mmol/mol (7%), although the effect is less strong and there is no greater risk of insulin treatment over triple oral therapy. These results are of interest, especially in the context of the outcomes of the ACCORD study where aggressive treatment initiated to achieve a treatment target of 48 mol/mol (6.5%) resulted in increased mortality compared with a less aggressive target [21]. Our findings show that people with Type 2 diabetes who are treated intensively to reach a mean HbA1c < 53 mmol/mol (7%) have much more variability between visits in their HbA1c than those who are likely closer to diagnosis requiring no treatment or monotherapy. At this level, 11.5% of the participants with highly variable HbA1c on triple oral therapy or insulin had at least one HbA1c reading < 37 mmol/mol (5.5%); whereas 46.2% of the same cohort had a reading > 69 mmol/mol (8.5%). If HbA1c variability per se is associated with increased risk of cardiovascular disease, this may explain the adverse outcomes found in ACCORD. Our findings support the rationale in the guidelines that emerged after ACCORD, that there should be a low HbA1c target in those early in the disease process and a less aggressive target once treatment has intensified [15,22]. It should be noted, however, that our
analysis cannot ascribe a causal association between intensive treatment regimens and high HbA1c variability. Individuals with high HbA1c variability will have large fluctuations in HbA1c that are likely to result in treatment intensification; conversely more intense treatment, especially with insulin, may result in more variability in glycaemic control.

In conclusion, we report, for the first time, the patient characteristics associated with high and low visit-to-visit variability in HbA1c. We have shown that intensive treatment is associated with high HbA1c variability, especially in those with a mean HbA1c < 53 mmol/mol (7%). We also demonstrate that those with high HbA1c variability are more likely to be male, younger and with low HDL-cholesterol. Further work is required to investigate how HbA1c variability varies over the life course of someone’s diabetes and with different diabetes treatments; and more complex models are required to account for underlying disease progression. Our findings suggest that those who are more likely to have high HbA1c variability are those who have more cardiovascular risk factors. Given this, it is uncertain whether the adverse cardiovascular disease outcomes reported to be associated with increased HbA1c variability can be attributed to the high HbA1c variability per se, or more simply reflects the high cardiovascular risk factors seen in people with Type 2 diabetes who exhibit high HbA1c variability. One potential way to unravel this causality question would be to use Mendelian randomization if suitable genetic instruments can be found.

Funding sources
The study was supported by the Wellcome Trust.

Competing interest
None declared.

Acknowledgements
We wish to acknowledge the help of the FARR Institute and the Health Informatics Centre, University of Dundee (Scotland, UK). E.R.P holds a Wellcome Trust Investigator Award 102820/Z/13/Z.

Author contributions
J.D.N. analyzed data and wrote the manuscript. E.S.P. researched data and wrote the manuscript. L.A.D. analyzed data. E.R.P. planned the study, contributed to the discussion and reviewed/edited the manuscript.

References
1 UK Prospective Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
2 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
3 Gotest C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK et al. Long-term glycaemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care 2015; 38: 2354–2369.
4 Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hame P et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in Type 2 diabetes: the ADVANCE trial. Diabetes Care 2014; 37: 2359–2365.
5 Jin S-M, Kim T-H, Bae JC, Hur KY, Lee M-S, Lee M-K et al. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. Diabetes Res Clin Pract 2014; 104: 266–272.
6 Greven WL, Beulens JWJ, Biesma DH, Faiz S, de Valk HW. Glycemic variability in inadequately controlled type 1 diabetes and Type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study. Diabetes Technol Ther 2010; 12: 695–699.
7 Kohnert K-D, Augstein P. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of Type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009; 32: 1058–1062.
8 Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Sources of glucose variability in insulin-treated Type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Clin Endocrinol (Oxf) 2004; 60: 451–456.
9 Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Metab 2001; 281: 924–930.
10 Monnier L, Mas E, Ginet C, Francoise M, Villon L, Cristol J et al. Activation of oxidative stress by insulin in patients with Type 2 diabetes. JAMA 2006; 295: 1681–1687.
11 Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with Type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther 2012; 14: 1008–1012.
12 Razavi Nematoollahi L, Kitabchi AE, Stentz FB, Wan JY, Larjani BA, Tehrani MM et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism 2009; 58: 443–448.
13 Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923–936.
14 Lemeshow S, Hosmer W. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115: 92–106.
15 Scottish Intercollegiate Network Guidelines (SIGN). Management of Diabetes. SIGN guideline 116. SIGN, Edinburgh, 2013.
16 Stoa EM, Meling S, Nyhus L-K, Glenn Stromstad G, Mangerud KM, Helgerud J et al. High-intensity aerobic interval training improves aerobic fitness and HbA1c among persons diagnosed with Type 2 diabetes. Eur J Appl Physiol 2017; 117: 455–467.
17 Bralic V, Bergman Marković B, Vrdoljak D. The association of lifestyle and stress with poor glycomic control in patients with diabetes mellitus Type 2: a Croatian nationwide primary care cross-sectional study. Croat Med J 2015; 56: 357–365.
18 Osborn C, Mayberry L, Kim J. Medication adherence may be more important than other behaviours for optimizing glycaemic control among low-income adults. J Clin Phar Ther 2016; 41: 256–259.
19 Chakera AJ, Steele AM, Glyn AL, Shepherd MH, Shields B, Ellard S et al. Recognition and management of individuals with
hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 2015; 38: 1383–1392.

20 Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014; 57: 54–56.

21 The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

22 National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG 28]. NICE, London, 2015.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Baseline characteristics of included and excluded participants.
Table S2. Univariate whole sample analysis showing the odds of high HbA1c variability.
Table S3. Sensitivity analysis 1: multivariate analysis showing the odds of high HbA1c variability with extreme mean HbA1c values removed.
Table S4. Sensitivity analysis 2: multivariate whole sample analysis showing the odds of high HbA1c variability with further differentiation of treatment groups.
Table S5. Sensitivity analysis 3: multivariate analysis showing the odds of high HbA1c variability with participants that changed treatment therapy removed.